Back
Ultragenyx Pharmaceutical Inc (RARE)
BiotechnologyRARE · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$26.45
+2.82%Weekly undervalued picks (like RARE)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-5.83
ROE
Gross margin
-28.1%
Debt/Equity
Revenue growth
-2.2%
P/B ratio
Beta
Forward P/E
Ultragenyx Pharmaceutical Inc — company intelligence
Earnings surprises
Q2 2026$-0.90 vs $-1.24 est+27.4%
Q1 2026$-1.84 vs $-1.54 est-19.5%
Q4 2025$-1.29 vs $-1.11 est-15.8%
Q3 2025$-1.81 vs $-1.26 est-43.7%
Analyst consensus · 25 analysts
22 Buy3 Hold0 Sell
Updated Aug 17, 2026
Insider activity · 90 days
0 buys6 sellsnet -19,846 shares
Horn HowardSell 4,696 · Aug 3, 2026
Parschauer Karah HerdmanSell 1,900 · Aug 3, 2026
Horn HowardSell 4,698 · Jul 1, 2026
Recent SEC filings
8-K — Material event reportAug 19, 2026
8-K — Material event reportAug 11, 2026
10-Q — Quarterly reportAug 5, 2026
Latest news
Ultragenyx: Undervalued Ahead Of Two FDA Decisions — SeekingAlpha · 1w ago
HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $50 Price Target — Benzinga · 2w ago
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45 — Benzinga · 2w ago
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript — SeekingAlpha · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like RARE)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.